Table A12.
HPV-FRAME reporting standards for evaluations assessing alternative vaccine types or reduced-dose schedules.∗
| a) Inputs | Reported? (Y/N) | Report by Age? (Y/N) | Report by sex? (B, F, M) | Comments |
|---|---|---|---|---|
| Vaccine efficacy/waning | Y | Y | Y | Level and duration of protection (waning function) by dose, type, age. (For 2-dose regimen: specify if each dose received is modelled and the efficacy modelled for each dose). |
| Timing between doses (for 2-dose) | Y | N/A | Y | |
| Vaccine cross-protection | Y | N/A | N/A | Level and duration of protection by dose and type |
| Cost |
Y |
N/A |
N/A |
Cost per dose, cost per vaccinated individual, and all vaccine cost assumptions including infrastructure, administration. |
| b) Outputs |
Reported? (Y/N) |
Report by Age? (Y/N) |
Report by sex? (B, F, M) |
Report as calibration or validation target? (Y/N) |
| Threshold cost per dose | Y | N/A | N/A |
B: both sexes, F: female only; M: male only; N: no; N/A: not applicable; Y: yes.
∗
HPV-FRAME core reporting standards are also applicable.